Dystrophin gene — Drug Target
All drugs that target Dystrophin gene — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Phase 3 pipeline (2)
- SRP-4045 · Sarepta Therapeutics, Inc. · Gene therapy · Muscular dystrophy
SRP-4045 is a micro-dystrophin gene therapy that aims to treat Duchenne muscular dystrophy by providing a functional copy of the dystrophin gene. - SGT-003 · Solid Biosciences Inc. · Gene therapy · Muscular dystrophy
SGT-003 is a gene therapy that aims to deliver a functional dystrophin gene to muscle cells.
Phase 2 pipeline (1)
- CX501 · Tigenix S.A.U. · Muscular Dystrophy
CX501 is a gene therapy that aims to increase the production of dystrophin in patients with Duchenne muscular dystrophy.